NeuroBo, Gemphire merger wrapped up to form neurodegenerative disease company
January 13, 2020 No Comment
NeuroBo Pharmaceuticals, a Boston-based clinical-stage pharma company, has wrapped up its previously announced merger with Gemphire Therapeutics, a Michigan-based clinical-stage biopharma company focused on developing therapies for dyslipidemia and nonalcoholic fatty liver disease (NASH). The new combined company will be called NeuroBo Pharmaceuticals, which will focus on advancing a clinical-stage pipeline targeting neurodegenerative diseases. NeuroBo, […]
Continue reading …
Taro Pharmaceuticals U.S.A. has issued to recall of a lot of Lamotrigine 100 mg tablets owing to cross-contamination with a trace of another drug substance – Enalapril Maleate. Lamotrigine is indicated for the treatment of epilepsy and bipolar disorders. The US pharmaceutical manufacturer is recalling Lot # 331771, which has an expiration date June 2021 […]
Continue reading …PACT Pharma raises $75m to develop neoTCR-T cell therapies for solid tumors
January 11, 2020 No Comment
PACT Pharma, a California-based clinical stage company, which is focused on developing fully personalized neoTCR-T cell therapies for solid tumors, has raised $75 million in a Series C financing round. The funding round was led by Vida Ventures, a life science venture firm, with participation from the current investors of PACT Pharma. The clinical stage […]
Continue reading …ATAI Life Sciences partners with Neuronasal to develop concussion treatment
January 7, 2020 No Comment
ATAI Life Sciences, a German biotech company focused on developing drugs for mental illnesses, has partnered with Neuronasal to develop a short-term treatment for mild traumatic brain injury (mTBI) or concussion. Neuronasal’s concussion treatment includes the intranasal delivery of low doses of N-acetylcysteine (NAC) to patients with acute concussion. N-acetylcysteine has been safely used for […]
Continue reading …
Chinese pharma company CF PharmTech has secured a $90 million Series E investment led by New Alliance Capital for accelerating the global development of respiratory drugs. The investment round saw participation from new investors such as CR-CP Life Science Fund, Finnova Capital, Xiangcheng Financial, GT Capital, Co-stone Asset Management, and Everest Venture Capital. Existing investors […]
Continue reading …
Astellas acquisition of Xyphos : Japanese pharma company Astellas Pharma has acquired US biotech company Xyphos Biosciences in a deal worth up to $665 million as per the latest pharma acquisition news. The acquisition of Xyphos Biosciences gives Astellas Pharma access to the former’s ACCEL technology platform alongside its immuno-oncology talent to develop new and […]
Continue reading …
Roche has signed a licensing deal worth up to $2.85 billion with Sarepta Therapeutics for the exclusive ex-US commercial rights to the latter’s SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), an investigational gene therapy for Duchenne muscular dystrophy (DMD). As per the agreement terms, Sarepta Therapeutics will get an upfront payment made up of $750 million in cash and $400 […]
Continue reading …
Charles River acquisition of HemaCare : Charles River Laboratories International, an early-stage contract research organization, has agreed to acquire HemaCare for about $380 million in an all-cash deal, as per the latest pharma acquisition news. HemaCare is engaged in the production of human-derived cellular products for the cell therapy market. The company provides critical biomaterials, […]
Continue reading …
US industrial conglomerate 3M has signed a cash-cum-stock deal worth around $650 million to sell substantially all of its drug delivery business to an affiliate of Altaris Capital Partners for about $650 million, as per the latest pharma acquisition news. As per the terms of the deal, the total consideration includes cash, an interest-bearing security, […]
Continue reading …Leucadia launches Sodium Tetradecyl Sulfate injection for varicose veins
December 12, 2019 No Comment
Leucadia Pharmaceuticals, the commercial sales unit of Custopharm, has launched the FDA-approved Sodium Tetradecyl Sulfate (STS) generic injection in the US. According to Leucadia Pharmaceuticals, the regulated sclerosing agent is therapeutically equivalent to SOTRADECOL and is an effective and safe alternative to the use of unapproved compounded products. Sodium Tetradecyl Sulfate is used for the […]
Continue reading …
Business News Today
- Nationwide, Generali to create N2G Worldwide Insurance Services JV
- Manna Tree Partners invests in organic beef producer Verde Farms
- Pernod Ricard rolls out caviar-infused vodka – L’Orbe Vodka x Caviar
- Skogul oil field : Aker BP set to begin production from Norwegian oil field
- COSMIC-311 clinical trial : Exelixis enrolls patients to study cabozantinib in phase 3 thyroid cancer trial
- Cystic fibrosis drug KALYDECO to be launched in New Zealand by Vertex Pharmaceuticals
- Sara Lee Frozen Bakery to acquire Cyrus O’Leary’s Pies
- Hexion to sell paint manufacturing plant in Yumbo, Colombia
- Essence Healthcare to acquire Mutual of Omaha’s Medicare Advantage business
- PepsiCo to acquire Chinese snack brand Be & Cheery for $705m
